CalciMedica, Inc. (NASDAQ:CALC) Director Fred A. Middleton Acquires 87,744 Shares of Stock

CalciMedica, Inc. (NASDAQ:CALC) Director Fred A. Middleton bought 87,744 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were bought at an average cost of $3.75 per share, with a total value of $329,040.00. Following the purchase, the director now directly owns 814,300 shares of the company’s stock, valued at approximately $3,053,625. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

CalciMedica Trading Up 1.1 %

NASDAQ:CALC opened at $3.54 on Wednesday. The company has a market cap of $38.06 million, a P/E ratio of -2.53 and a beta of 1.30. CalciMedica, Inc. has a twelve month low of $2.68 and a twelve month high of $8.38. The company’s 50-day moving average price is $4.24 and its 200-day moving average price is $4.63.

CalciMedica (NASDAQ:CALC) last released its earnings results on Monday, August 12th. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.03. On average, analysts expect that CalciMedica, Inc. will post -2.21 earnings per share for the current year.

Hedge Funds Weigh In On CalciMedica

An institutional investor recently raised its stake in CalciMedica stock. Atria Investments Inc grew its stake in CalciMedica, Inc. (NASDAQ:CALC) by 136.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 26,503 shares of the company’s stock after acquiring an additional 15,296 shares during the quarter. Atria Investments Inc owned about 0.25% of CalciMedica worth $117,000 as of its most recent SEC filing.

Analyst Upgrades and Downgrades

CALC has been the subject of several research reports. HC Wainwright cut their price objective on CalciMedica from $20.00 to $16.00 and set a “buy” rating for the company in a research note on Monday. Oppenheimer lifted their price target on CalciMedica from $14.00 to $20.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 10th.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.